You are currently visiting our global website. DREAMM-9: Phase 3 Study of Belantamab Mafodotin Plus VRd vs VRd Alone in Transplant Ineligible Newly Diagnosed Multiple Myeloma (TI NDMM), 10.

DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. Trends Cancer. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. REF—US-000633 Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated U.S. COVID-19. [Poster No. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. [Poster No. © 2020 GSK group of companies or its licensor. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare.

Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism.

REF—US0000604 Meningococcal Vaccination Among Patients Newly Diagnosed at High-Risk For Meningococcal Disease in the US, 1.

Autologous T cells with NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-A*02+ previously treated and untreated advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO), 3. A range of products to help provide effective relief from nicotine cravings. Theraflu (Respiratory) Tums (gastrointestinal) Viva (vitamins and naturals) Origin: Nepal; Zovirax (dermatological) Sport supplements products. [Poster No. Trade marks are owned by or licensed to the GSK group of companies. 3888792. PD-1, or programmed cell death protein 1, is a key immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell–mediated immune responses. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. By clicking this link, you will be taken to a website that is independent from GSK. 2017;31(2):101-126. Learn more online today. Explore respiratory videos, resources, congress presentations & more.

1.

You are recommended to use an alternate browser such as Chrome, Opera or FireFox. We’ll send you an email with the result of the validation process in the next 3 working days. Presentation: Time to First Subsequent Therapy (TFST) and Progression-Free Survival 2 (PFS2) From the Phase 3 Randomized, Double-Blind PRIMA/ENGOT-OV26/GOG-3012 Study in Patients With Newly Diagnosed Ovarian Cancer Study SGO 2020, 2. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Tabberer M, von Maltzahn R, Bacci E, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma.

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles.

Patients with Uncontrolled Asthma Eligible for a Biologic.

INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 16. [Oral presentation available here; Abstract A4212].

This site is intended for UK healthcare professionals only. [Poster No. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. www.vaers.hhs.gov to file a report, or call [Poster No. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1.

2004;199(1):91-98.

Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.

REF—US-000629 Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction, 3. Trade marks are owned by or licensed to the GSK group of companies. [Poster No. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). *Nielsen Total Coverage, volume sales w/e 07.09.19. P805; Abstract A7742]. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. 1-888-825-5249, or call the FDA at

5. This site is intended for UK healthcare professionals only.

Publication Only: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, Publication Only: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, Publication Only: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM), Publication Only: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, Publication Only: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, Publication Only: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS), Publication Only: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Epigenetics. REF—US-000632 Eliciting Preference for Zoster Vaccination in US Adults Aged 50 Years and Older, 6. Abstract: Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer, 2. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. [Poster No. This website is operated by GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, a company registered in England and Wales under company number 09237643 with its registered office at 980 Great West Road, Brentford, Middlesex, UK, TW8 9GS. Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape.

Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. mcg) Inhalation Aerosol, (umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder), (fluticasone furoate inhalation powder) 100 mcg and 200 mcg, (beclomethasone dipropionate, monohydrate) Nasal Spray, 42 mcg, (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder), 50 mcg/100 mcg/250 mcg (fluticasone propionate inhalation powder, 50 mcg/100 mcg/250 mcg), HFA 44 mcg/110 mcg/220 mcg (fluticasone propionate 44 mcg/110 mcg/220 mcg) Inhalation Aerosol, (umeclidinium 62.5 mcg inhalation powder), (mepolizumab) for injection, for subcutaneous use, (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), Presented by: Dr. Michael E. Wechsler, MD, MMSc, Blood Eosinophil Unit Conversion Calculator, American Academy of Allergy, Asthma & Immunology, American Association for Respiratory Care, American College of Allergy, Asthma & Immunology, Centers for Disease Control and Prevention Asthma Information, Centers for Disease Control and Prevention COPD Information, Global Initiative for Chronic Obstructive Lung Disease, National Heart, Lung, and Blood Institute, PhactMI Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, 1. Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. Complementing our world leading Pharmaceuticals respiratory business, we are the number one over the counter respiratory medicine company with a complete portfolio of leading brands in cold and flu, nasal decongestant, allergy and smoking cessation, Theraflu is a leading brand of over-the-counter medicine that provides fast and powerful relief of cold and flu symptoms, Otrivin is the world’s leading nasal decongestant brand, Flonase allergy relief is an allergy medicine that works directly in the nose to help allergy reactions, Contac is a nasal decongestant tablet that also relieves pain and reduces a fever, Nicotinell is a smoking cessation treatment range that includes patch, gum and lozenge, Nicorette, is a nicotine replacement therapy available in gum or lozenge form designed to help smokers quit their nicotine addiction, Safety Data Sheets (SDS) and environmental information on prescription medicines.

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. 11. Safety and tolerability of autologous T cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: a phase 1b/2a randomized pilot study, 7. 2016;126(7):2404-2411. 6.

Not a healthcare professional? Please update your operating system or use a different device. Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS®: Asthma in Two Clinical Trials of Moderate to Severe Asthma.

Adults ≥50 Years of Age, 7. 714; Abstract A4267].